This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence

Joseph P. McEvoy, MD

Published: September 29, 2020


Tardive dyskinesia (TD) is a condition of potentially irreversible abnormal involuntary movements associated with dopamine receptor blocking agents, such as antipsychotics. While prevention is the best strategy, it is not always possible. This report outlines strategies to reduce TD symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).

From the Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Georgia.

To cite: McEvoy JP. Selecting treatment for patients with tardive dyskinesia using safety and efficacy evidence. J Clin Psychiatry 2020;81(6):NU19047BR3C
To share:

© Copyright 2020 Physicians Postgraduate Press, Inc.

See the entire activity.

Volume: 81

Quick Links: Side Effects-Medication , Tardive Dyskinesia


Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...